Totally implantable venous access devices in adult patients with cystic fibrosis  by Yung, B. et al.
Respiratory Medicine (1996) 90, 353-356 
Totally implantable venous access devices in adult 
patients with cystic fibrosis 
B. YuNG*$, I. A. CAMPBELL*, J. S. ELBORN”, J. S. HARVEY? AND D. J. SHALE* 
*Section of Respiratory Medicine, University of Wales College of Medicine, and TDepartment of Surgery, 
Llandough Hospital NHS Trust, Penarth, South Glamorgan, Wales, U.K. 
Between September 1987 and April 1995, 33 totally implantable venous access devices (TIVADs) were 
implanted at the Cardiff Adult Cystic Fibrosis Centre, U.K., for the purpose of intermittent antibiotic 
therapy, including 22 PORT-A-CATH@ (Simcare Ltd.) devices (PCs) to 18 patients, and 11 P.A.S.PORT@ 
(Simcare Ltd.) devices (PPs) to nine patients. There were 50 complications during 25 824 days of catheter 
function which were severe enough to lead to removal of the devices in eight patients (six PCs and four PPs). 
Overall, patients’ acceptance of these devices was excellent. Despite a shorter functional time and a higher rate 
of complications in PPs compared with PCs, PPs were preferred by many patients for cosmetic reasons. 
Totally implantable venous access devices provide safe, effective and convenient means of venous access in 
cystic fibrosis patients requiring intermittent antibiotic therapy. 
Introduction 
Many patients with cystic fibrosis (CF) and 
chronic Pseudomonas aeruginosa and/or Burkholderia 
cepacia pulmonary infection require frequent inter- 
mittent intravenous antibiotic therapy for treatment 
of infective exacerbations. The use of intravenous 
cannulae is associated with a high incidence of 
thrombophlebitis (l), and repeat venepuncture of 
peripheral veins often results in venous thrombosis. 
Difficult venous access and needle phobia in some 
patients pose additional problems. 
Totally implantable venous access devices 
(TIVADs) provide an alternative means of venous 
access and have been used successfully in oncology 
patients requiring intermittent chemotherapy for 
some years (2,3). The use of TIVADs in patients with 
CF was first described in 1986 (4). Since then, only a 
limited number of reports have been published on the 
use of such devices in this group of patients (5-9). 
Experience has ranged from 8 months (5) where there 
were few problems associated with TIVADs, through 
to 6 years where there were problems with catheter 
occlusion, venous thrombosis and infection (6-9). An 
audit of the use of such devices was undertaken in the 
authors’ patients in the Adult Cystic Fibrosis Centre 
over a period of 8 yr. 
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Materials and Subjects 
Two types of TIVADs are used in the authors’ 
centre. A PORT-A-CATH@ (Simcare Ltd.) device 
(PC) consists of a silicone or polyurethane catheter 
attached to a titanium portal with a self-sealing 
septum. The catheter is introduced into a central vein 
using aseptic technique. The portal is inserted subcu- 
taneously, usually on the anterior chest wall, via a 
second incision. The catheter is then tunnelled sub- 
cutaneously and connected to the portal. When in 
use, a Huber needle is used to penetrate the septum, 
and antibiotics can be injected percutaneously. A 
P.A.S.PORTa (Simcare Ltd.) device (PP) is a similar 
but smaller device with its portal usually placed in the 
arm. Patients are given detailed written and verbal 
information regarding the care and use of such 
devices prior to and after the implantation of their 
devices. All patients are admitted the evening prior to 
surgery for medical and anaesthetic assessment. 
When not in use, TIVADs are flushed monthly 
with heparinized saline (100 IU ml - ‘) under aseptic 
technique by trained nursing staff. 
The first PC was implanted in 1987 and the first PP 
was implanted in 1992. These were used chiefly for 
antibiotic administration, although blood sampling 
was performed on rare occasions for blood cultures. 
The majority of devices (26 of the 33 devices) were 
implanted under the supervision of one surgeon 
(JSH):The case records of the patients with TIVADs 
implanted from September 1987 to the end of April 
1995 were reviewed. 
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Table I Routes of catheter cannulation of TIVADs 
IJ Sub C I B Total 
PC 11 3 I 1 0 22 
PP 0 10 0 0 1 11 
PC, PORT-A-CATH@; PP, P.A.S.PORT@; IJ, internal 
jugular vein; Sub, subclavian vein; C, cephalic vein; I, iliac 
vein; B, brachial vein; TIVADs, totally implantable venous 
access devices. 
Results 
Between September 1987 and April 199.5, 33 
TIVADs were implanted in the authors’ centre, 
including 22 PCs in 18 patients (five male: 13 female) 
and 11 PPs in nine patients (two male: seven female). 
Four patients had two PCs implanted, two patients 
had two PPs implanted and two patients had both a 
PC and a PP implanted. The median age of patients 
at implantation was 20 years (range 1540 years) and 
their median FEV, at implantation was 28% of 
predicted (range 1 l-94%). 
All but two patients in the PC group and all but 
one patient in the PP group had their devices 
implanted under general anaesthesia. The routes of 
catheter insertion are summarized in Table 1. 
During the study period, the time during which the 
PCs were in place and remained functional ranged 
from 99 to 2219 days (median 1146 days); the corre- 
sponding figures for PPs were 7 to 1054 days (median 
248 days). There were 50 complications over a total 
of 25 824 catheter functional days (Table 2); a com- 
plication rate of one every 516 days of catheter 
function (PC: one episode in 625 days; PP: one 
episode in 207 days). 
One patient, who had a PC implanted under local 
anaesthesia and sedation, deteriorated immedi- 
ately following implantation, probably as a result of 
over-sedation. She was intubated and required a brief 
period of mechanical ventilation but made a full 
recovery. All patients had post-operative chest 
radiographs performed and no pneumothorax was 
identified. 
Late complications can be divided into infective or 
mechanical. There were five episodes of infection in 
four patients (Table 2), including three episodes of 
site infection, which is defined as positive swabs from 
the needle puncture site with associated signs of 
inflammation. All such episodes resolved follow- 
ing intravenous antibiotic therapy. One patient 
developed fungaemia with pyrexia and pain at the PC 
site 53 months following implantation; culture of 
blood taken from the peripheral vein and from the 
Table 2 Complications related to the use of TIVADs 
(episodes) 
PC PP 
Early Over-sedation requiring ventilation 1 0 
Poor wound healing 1 0 
Late Catheter occlusion 19 3 
Infection 2 3 
Portal protrusion leading to removal 2 2 
Thrombosis and/or embolism 3 0 
Catheter migration requiring revision 0 1 
Catheter dislodged 0 1 
Pain from portal 4 2 
Difficult to needle 3 0 
Poor skin healing after use 2 1 
Total 37 13 
PC, PORT-A-CATH@ (n=22); PP, P.A.S.PORT@ (n= 11). 
portal revealed growth of Candida parapsilosis. The 
PC was removed and she recovered fully following a 
3-week course of intravenous amphotericin. A second 
patient presented with episodes of rigor and head- 
ache 4 months following implantation. Blood culture 
taken from his peripheral vein and from the portal of 
his PP revealed growth of Pseudomonas aeruginosa. 
The device was removed and he recovered with 
intravenous antibiotic therapy. 
Catheter occlusion is relatively common and is 
presumably due to thrombus formation within or at 
the tip of the catheter. This complication usually 
resolved with the use of heparin or urokinase. There 
were two patients with venous thrombosis, confirmed 
on venogram, requiring removal of the devices and 
a period of anticoagulant therapy. Another patient 
had a thrombus at the tip of her PC identified 
by two-dimensional echocardiogram 5 yr following 
implantation. This was complicated by pulmonary 
embolism. She recovered fully following thrombo- 
lytic therapy and is now on long-term warfarin 
treatment. Her PC remains functional. 
During the study period, six PCs and four PPs 
were removed as a result of complications (Table 3). 
One PC was removed after the patient received a 
successful heart-lung transplant. Seven patients who 
had TIVADs implanted died during the study period, 
but none of the deaths was related to their devices. 
All surviving patients with TIVADs in situ at 
present or at some stage in the past were interviewed 
by telephone during the last week of April 1995. 
Patients were asked to rate their overall satisfaction 
with the devices (1 = totally dissatisfied; 5 = totally 
satisfied). Patients in both the PC and the PP group 
expressed a high degree of satisfaction with their 
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Table 3 Complications leading to removal 
Device 
number 
Functional time 
prior to 
removal (days) Reasons for removal 
PORT-A-CATH@ 
1 99 
2 169 
3 666 
4 162 
5 1514 
6 1620 
P.A.S.PORTa 
1 17 
2 131 
3 264 
4 323 
Venous thrombosis 
Venous thrombosis 
Blockage 
(no thrombus identified) 
Portal protrusion 
Portal protrusion 
Fungaemia 
Catheter dislodged 
Septicaemia 
Portal protrusion 
Portal protrusion 
devices, with PCs and PPs having median ratings of 
4.5 and 4.0, respectively. All patients would undergo 
another TIVAD insertion in the future although, for 
cosmetic reasons, three out of 11 patients in the PC 
group and four out of five patients in the PP group 
preferred to have a PP implanted. The rest of the 
patients expressed no preference. 
Discussion 
Totally implantable venous access devices have 
been used in oncology since 1982 and have a lower 
incidence of infection and thrombosis compared to 
external systems (2,3). These devices have the addi- 
tional advantages of being convenient to use and easy 
to manage. Since the use of a PC was first described 
in a patient with CF in 1986 (4), only a limited 
number of reports have been published on the use of 
such devices in this group of patients, particularly 
with the use of the PP devices which were introduced 
in 1988 (10). In contrast to most series (5,7,8), 
most of the patients in the present study had their 
devices implanted under general anaesthesia. General 
anaesthesia is preferred by the authors’ surgeon 
because the implantation procedure is less likely to be 
disturbed by patients’ activities such as coughing and 
movement. The patients tolerated the procedure well 
despite the severity of the pulmonary disease. No 
pneumothorax was identified, compared to a rate of 
4.4% reported by Morris et al. (8). This is likely to be 
the result of a relatively smaller number of cases 
with the subclavian vein as the route of catheter 
cannulation in the present series. The occurrence of 
pneumothorax would be particularly undesirable in 
this group of patients with existing severe lung 
impairment. 
There were 50 episodes of complications in 33 
devices over a period of 8 yr. Catheter occlusion, 
presumably due to the presence of small thrombi 
within or at the tip of the catheter, accounted for a 
large proportion of the complication episodes. In the 
study centre, a 30 ml syringe containing 5 ml of 
heparinized saline (10 IU ml - ‘) is used to irrigate 
and aspirate the device alternatively when the 
authors attempt to clear small thrombi. On the rare 
occasions when occlusion persists, 0.2 ml of uro- 
kinase (5000 IU ml - ‘) is injected into the device and 
aspiration of the clot is attempted after 20 min. These 
steps are repeated until the catheter clears. 
Three episodes of venous thrombosis were con- 
firmed during the use of 33 devices over a period of 
8 yr, compared with three episodes of superior vena 
caval syndrome or venous thrombosis in 22 TIVADs 
over a 6-yr period as reported by Sola et al. (9). The 
recognized risk of thrombotic events related to the 
use of TIVADs leads Sola et al. to recommend 
the prophylactic use of aspirin in all CF patients with 
such devices who have no evidence of liver disease or 
bleeding problems(g). One of the present authors’ 
patients had pulmonary embolism from the throm- 
bus, a complication not previously reported with the 
use of TIVADs in CF patients. 
The present infection rate of five episodes in 33 
devices (15.2%) over a period of 8 yr is comparable to 
the reported 17.6% in 68 devices over 4.5 yr (8). The 
present series included a patient with fungaemia. 
Risk factors for this complication include: severe 
underlying lung disease; acute infective exacerbation, 
malnutrition, frequent use of broad spectrum anti- 
biotics; parental nutrition; and diabetes mellitus. 
Removal of the device in such a situation is essential 
(11). 
In common with other studies, the authors found 
that PCs provide safe and reliable long-term venous 
access for this group of patients. The relatively high 
complication rates and short functional time related 
to PPs is in common with Conway et al.‘s experience 
with 65 PPs inserted in 57 patients which was 
published in an abstract (12). Portal protrusion was a 
significant problem, accounting for four of the 10 
removals including two of the four PPs removed. 
This complication may be related to the relatively 
small amount of subcutaneous tissue in these usually 
poorly nourished patients (8). 
Totally implantable venous access devices were 
generally well accepted by patients. Despite being 
well informed of the shorter functional time and the 
higher complication rates of PPs, most patients opted 
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to have this device implanted as they are’ more 
acceptable cosmetically. Indeed, since September 
1993, all of the seven patients requiring TIVADs 
have chosen PPs, reflecting the popularity of these 
devices. 
In the authors’ centre, TIVADs are recommended 
to selected patients in whom their use quickly 
becomes a matter of simple routine. These devices 
provide safe, effective and convenient means of 
venous access for patients who require intermittent 
antibiotic therapy and are prepared to care for such 
devices over long periods. In the selection of a device, 
patient preference is a strong factor which may 
sometimes over-ride choice based solely on func- 
tional efficiency. It is essential that patients are fully 
informed regarding the merits of various devices, and 
that proper comparisons are made between devices as 
new ones are introduced into clinical practice. 
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